Dual Functional Radioactive Gel-Microspheres for Combinatorial Radioembolization and Photothermal Therapy of Hepatocellular Carcinoma.

IF 10 2区 医学 Q1 ENGINEERING, BIOMEDICAL
Jing Sun, Xingwei Sun, Liang Yin, Shuo Jin, Qian Huang, Yi Dong, Xiaolei Gu, Yujuan Zhang, Yong Jin, Ran Zhu, Guanglin Wang
{"title":"Dual Functional Radioactive Gel-Microspheres for Combinatorial Radioembolization and Photothermal Therapy of Hepatocellular Carcinoma.","authors":"Jing Sun, Xingwei Sun, Liang Yin, Shuo Jin, Qian Huang, Yi Dong, Xiaolei Gu, Yujuan Zhang, Yong Jin, Ran Zhu, Guanglin Wang","doi":"10.1002/adhm.202401057","DOIUrl":null,"url":null,"abstract":"<p><p>Transarterial radioembolization (TARE) is an established clinical therapy for treating patients with intermediate to advanced hepatocellular carcinoma (HCC) or those who cannot undergo radical treatment. However, the delivery of a high radiation dose is associated with several adverse effects, such as radiation pneumonitis. Additionally, the available radioactive microspheres (MSs) are dense and unsuitable for interventional delivery. This study proposes the use of commercial CalliSpheres polyvinyl alcohol (PVA) gel MSs coated with polydopamine (PDA) as a carrier for radioactive iodine (<sup>131</sup>I) labeled using the iodogen method, denoted as <sup>131</sup>I-PDA@PVA MSs, which can be for radioembolization combined photothermal therapy (PTT) of HCC. In vitro experiments have demonstrated that <sup>131</sup>I-PDA@PVA MSs have high radiolabeling stability and photothermal properties. Single photon emission computed tomography (SPECT)/computed tomography (CT) imaging and biodistribution experiments have shown that <sup>131</sup>I-PDA@PVA MSs remain stable in vivo without any radioactive leakage. The results of the antitumor study suggest that <sup>131</sup>I-PDA@PVA MSs are an effective treatment for inhibiting tumor growth through a combination of radioembolization and PTT while avoiding significant side effects. These multifunctional MSs have great potential for clinical application in the treatment of HCC.</p>","PeriodicalId":113,"journal":{"name":"Advanced Healthcare Materials","volume":" ","pages":"e2401057"},"PeriodicalIF":10.0000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Healthcare Materials","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1002/adhm.202401057","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Transarterial radioembolization (TARE) is an established clinical therapy for treating patients with intermediate to advanced hepatocellular carcinoma (HCC) or those who cannot undergo radical treatment. However, the delivery of a high radiation dose is associated with several adverse effects, such as radiation pneumonitis. Additionally, the available radioactive microspheres (MSs) are dense and unsuitable for interventional delivery. This study proposes the use of commercial CalliSpheres polyvinyl alcohol (PVA) gel MSs coated with polydopamine (PDA) as a carrier for radioactive iodine (131I) labeled using the iodogen method, denoted as 131I-PDA@PVA MSs, which can be for radioembolization combined photothermal therapy (PTT) of HCC. In vitro experiments have demonstrated that 131I-PDA@PVA MSs have high radiolabeling stability and photothermal properties. Single photon emission computed tomography (SPECT)/computed tomography (CT) imaging and biodistribution experiments have shown that 131I-PDA@PVA MSs remain stable in vivo without any radioactive leakage. The results of the antitumor study suggest that 131I-PDA@PVA MSs are an effective treatment for inhibiting tumor growth through a combination of radioembolization and PTT while avoiding significant side effects. These multifunctional MSs have great potential for clinical application in the treatment of HCC.

经动脉放射栓塞术(TARE)是一种成熟的临床疗法,用于治疗中晚期肝细胞癌(HCC)患者或无法接受根治性治疗的患者。然而,高剂量的放射线会带来一些不良反应,如放射性肺炎。此外,现有的放射性微球(MS)密度较高,不适合用于介入治疗。本研究提出使用涂有聚多巴胺(PDA)的商用 CalliSpheres 聚乙烯醇(PVA)凝胶 MSs 作为载体,以碘原法标记放射性碘(131I),称为 131I-PDA@PVA MSs,可用于 HCC 的放射栓塞联合光热疗法(PTT)。体外实验证明,131I-PDA@PVA MSs 具有较高的放射性标记稳定性和光热特性。单光子发射计算机断层扫描(SPECT)/计算机断层扫描(CT)成像和生物分布实验表明,131I-PDA@PVA MSs 在体内保持稳定,没有任何放射性泄漏。抗肿瘤研究结果表明,131I-PDA@PVA MSs 是一种通过放射性栓塞和 PTT 组合抑制肿瘤生长的有效治疗方法,同时避免了明显的副作用。这些多功能 MSs 在治疗 HCC 的临床应用中具有巨大潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advanced Healthcare Materials
Advanced Healthcare Materials 工程技术-生物材料
CiteScore
14.40
自引率
3.00%
发文量
600
审稿时长
1.8 months
期刊介绍: Advanced Healthcare Materials, a distinguished member of the esteemed Advanced portfolio, has been dedicated to disseminating cutting-edge research on materials, devices, and technologies for enhancing human well-being for over ten years. As a comprehensive journal, it encompasses a wide range of disciplines such as biomaterials, biointerfaces, nanomedicine and nanotechnology, tissue engineering, and regenerative medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信